Literature DB >> 7953301

Presentation and recognition of major and minor histocompatibility antigens.

A N Warrens1, G Lombardi, R I Lechler.   

Abstract

The structural basis of allorecognition is heterogeneous. For minor histocompatibility antigen-specific T cells and for a minority of anti-MHC T cells (indirect allorecognition), the allogeneic molecule acts as any other protein, and is processed and presented as a peptide in the context of self MHC. In circumstances where the MHC molecule is recognized unprocessed on the surface of the allogeneic cell, we have postulated that the factors important in recognition are determined by the relationship between the responder and stimulator MHC molecules. When the alloresponse is directed against an allogeneic molecule whose exposed surface closely resembles that of the responder homologue, the alloresponse can be regarded as resulting from mimicry of self MHC-restricted recognition of peptides which are differentially bound by responder and stimulator MHC molecules. When the alloantigen differs extensively in the MHC restriction-determining region of the molecule from the equivalent product in the responder, a chance high-affinity cross-reaction with the foreign MHC structure itself may be the most important mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7953301     DOI: 10.1016/0966-3274(94)90036-1

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  12 in total

1.  Antigenicity and immunogenicity of allogeneic retinal transplants.

Authors:  N G Anosova; B Illigens; F Boisgérault; E V Fedoseyeva; M J Young; G Benichou
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  T cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis.

Authors:  S R Duncan; V Valentine; M Roglic; D J Elias; K W Pekny; J Theodore; D H Kono; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

3.  On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses.

Authors:  X C Li; M S Zand; Y Li; X X Zheng; T B Strom
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

Review 4.  Immune recognition and rejection of allogeneic skin grafts.

Authors:  Gilles Benichou; Yohei Yamada; Seok-Hyun Yun; Charles Lin; Michael Fray; Georges Tocco
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

Review 5.  Loss of tolerance to self after transplant.

Authors:  Melissa R Keller; William J Burlingham
Journal:  Semin Immunopathol       Date:  2011-02-06       Impact factor: 9.623

Review 6.  The role of the Major Histocompatibility Complex in the spread of contagious cancers.

Authors:  Katherine Belov
Journal:  Mamm Genome       Date:  2010-10-21       Impact factor: 2.957

Review 7.  Pathways of major histocompatibility complex allorecognition.

Authors:  Behdad Afzali; Giovanna Lombardi; Robert I Lechler
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

8.  Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients.

Authors:  Oriol Bestard; Peter Nickel; Josep M Cruzado; Constanze Schoenemann; Olaf Boenisch; Anett Sefrin; Josep M Grinyó; Hans-Dieter Volk; Petra Reinke
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

Review 9.  Intercellular transfer of MHC and immunological molecules: molecular mechanisms and biological significance.

Authors:  L A Smyth; B Afzali; J Tsang; G Lombardi; R I Lechler
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

10.  Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.

Authors:  Adnan Khan; Hongmei Fu; Lee Aun Tan; Jennifer E Harper; Sven C Beutelspacher; Daniel F P Larkin; Giovanna Lombardi; Myra O McClure; Andrew J T George
Journal:  Eur J Immunol       Date:  2013-01-18       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.